Figure 4.

The effects of EZH2i and NAM in T cell differentiation states. (A) GSK343 treatment largely matches untreated subsets as tracked through in vitro stimulation time course, with significant increase in central memory subset on day five. NAM drives a high TEMRA proportion in both CD4+ and CD8+ T cells. (B) T cells were gated to IR+ cells and assessed for proportions of differentiation subset proportions, on day seven. Assessed by chi-squared analysis (* p < 0.05). TEMRA, T effector terminally differentiated; EM, effector memory; CM, central memory. (C) Treg phenotype tracked through treatment groups by mass cytometry (CD25+ CCR4+ of CD4+ T cells). (D) Representative plot showing T cells on day seven gated for CD4+ and CD8+ and as a tSNE representation, with CD8+ T cells highlighted in red, and of the CD8+ T cells, (E) positioning of IR+ cells (in red) and subsets (indicated by color key: TEMRA purple, EM aqua, CM pink and naïve black) across ex vivo comparison and the range of in vitro treatment conditions.